ProMIS Neurosciences, Inc. PMN.TO
Jul 21, 2023, 3:55 PM EDT
52-week range unavailable
- Market cap
- 31.31M
- Shares out
- 8.58M
- Forward P/E
- -1.97
- Volume
- 19.70K
- Open
- 6.49
- Previous close
- 6.00
- Day's range
- 5.98 – 6.49
- Beta
- 1.19
- Analysts
- Buy
Key statistics
- Enterprise value
- 32.66M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -8.46M
- Total cash
- 3.38M
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 0.03%
- 50-day average
- 6.59
- 200-day average
- 7.04
Analyst view
Consensus: buy
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- promisneurosciences.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on PMN.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Cashman (Neil) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jun 29, 2022 | 102,661 |
| Geffken Daniel E | Senior Officer of Issuer | Stock split or consolidation | Jun 27, 2022 | 5,852 |
| Goldstein (Elliot) | Director of Issuer | Stock split or consolidation | Jun 27, 2022 | 123,465 |
| Johanne (Kaplan) | Senior Officer of Issuer | Stock split or consolidation | Jun 27, 2022 | 4,817 |
| Kirwin (Patrick D) | Director of Issuer | Acquisition or disposition in the public market | Aug 15, 2022 | 41,982 |
| Lanier (Kristi Jane) | Senior Officer of Issuer | Stock split or consolidation | Jun 27, 2022 | 795 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Northeast Financial Consultants Inc | 1.17% | 100,000 | 365.00K | Mar 30, 2023 |
| IEQ Capital, LLC | 0.46% | 39,191 | 143.05K | Mar 30, 2023 |
| Bank of America Corporation | 0.17% | 14,715 | 53.71K | Mar 30, 2023 |
| Claret Asset Management Corp | 0.14% | 12,330 | 45.00K | Mar 30, 2023 |
| Fiduciary Trust Company (MA) | 0.12% | 10,158 | 37.08K | Mar 30, 2023 |
| JP Morgan Chase & Company | 0.06% | 5,196 | 18.96K | Mar 30, 2023 |
